Powell Andrew Kenneth William 4
4 · Aclaris Therapeutics, Inc. · Filed Jun 5, 2023
Insider Transaction Report
Form 4
Powell Andrew Kenneth William
Director
Transactions
- Award
Stock Option (Right to Buy)
2023-06-01+15,750→ 15,750 totalExercise: $8.70Exp: 2033-05-31→ Common Stock (15,750 underlying) - Exercise/Conversion
Common Stock
2023-06-02+4,507→ 14,363 total - Award
Restricted Stock Units
2023-06-01+4,660→ 4,660 total→ Common Stock (4,660 underlying) - Exercise/Conversion
Restricted Stock Units
2023-06-02−4,507→ 0 total→ Common Stock (4,507 underlying)
Footnotes (5)
- [F1]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
- [F2]This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy.
- [F3]The shares subject to this option will vest in twelve equal monthly installments commencing July 1, 2023, subject to Reporting Person's continuous service through each such date.
- [F4]The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date.
- [F5]The shares underlying these restricted stock units vested on June 2, 2023.